SELLAS Life Sciences Shares Soar 175% On Positive Phase 3 Cancer Trial Results

SELLAS Life Sciences (SLS) shares jumped 175% after reporting positive Phase 3 trial results for its cancer vaccine, GPS, in AML patients. The stock opened at $24.00, up from $7.47 the prior close, and traded between $1.39 and $24.89 over the past year.

Original reporting
Published Nov 17, 2026, 4:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 6:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$SLS
Bullish
medium confidence
Mentioned
$SLS
Relevance
9/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$SLSBullishMed
01

Why it matters

A positive pivotal Phase 3 topline readout is a major de-risking event for biotech development programs and typically drives sharp repricing, especially when the market had priced in uncertainty.

02

Market read

Traders can act on a fresh, company-specific clinical catalyst that triggered a large same-day move.

03

What to watch

The article provides no details on magnitude of benefit, statistical significance, or safety; traders may fade gains ahead of full readouts and regulatory clarity.

Relevance 9/10Novelty 8/10Timing: same-day reaction to Phase 3 topline results

Background

The company reported positive topline results from its pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML).

Company-level read

Ticker impact

$SLSBullishMedium confidence
Context

SELLAS shares surged 175% after announcing positive topline Phase 3 REGAL trial results for its AML cancer vaccine galinpepimut-S.

Expected impact

Likely continued upside pressure and high volatility as traders price in potential regulatory and confirmatory-trial momentum.

Evidence & confidence

The article attributes the outsized same-day move directly to positive Phase 3 topline results, a primary catalyst for biotech risk/reward repricing.

Market effects

Reinforces positive sentiment toward AML vaccine/immunotherapy development and can lift attention to similar late-stage oncology programs.

Primarily US small/mid-cap biotech sentiment, with spillover to broader biotech risk appetite.

Limited direct global impact beyond oncology trial-readthrough interest.

Counterpoint

Topline Phase 3 results can reverse on missing endpoints, safety signals, or weaker-than-expected effect sizes once full data are released.

Key entities

  • SELLAS Life Sciences Group, Inc.

    Subject of the article; shares surged after positive Phase 3 topline results for its AML cancer vaccine.

  • Galinpepimut-S (GPS)

    Investigational cancer vaccine evaluated in the pivotal Phase 3 REGAL trial.

  • REGAL trial

    Phase 3 pivotal study in AML whose topline results were reported as positive.

  • Acute myeloid leukemia (AML)

    Disease area targeted by the investigational vaccine in the trial.

Related articles

$NVDAMedAI 8/10

Futures Rise As Huang-less Nvidia Beats And Raises, Gold Crashes Below $3,800

US futures rise as Nvidia (NVDA) reports strong earnings and raises guidance, boosting AI-related stocks. Gold drops below $3,800 after Fed Governor Waller's comments. Nvidia's Q4 revenue guidance is $130B vs. estimates of $125B. Premarket movers include TSLA, GOOGL, AMZN, AAPL, META, AVGO, CRWV, AAOI, BLSH, DLB, LOW, SLS, TTWO, TNDM. Fed policy and economic data releases are in focus.

$SLSHighAI 9/10

SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From Here

Sellas Life Sciences (SLS) reported positive Phase 3 trial results for its cancer vaccine, Galinpepimut-S (GPS), showing a 24-month median survival vs. 14.7 months in the control group. The company plans to meet with the FDA and aims to file for approval in early 2027. SLS also announced a $150M share offering to fund further development. Analysts and investors reacted positively, with some noting potential for expedited approval and broader applications.

$SLSHighAI 9/10

SLS Joins MRNA And ANL In Biotech’s Top 3 Winners This Year — Can Sellas Deliver Another Double From Here?

Sellas Life Sciences (SLS) stock surged 156% to $19.15 after positive Phase 3 trial results for its leukemia vaccine, Galinpepimut-S. The trial showed a 41% reduction in death risk, with median survival of 24 months vs. 14.7 months in the control group. Maxim Group raised its price target to $40, citing significant upside potential. SLS is planning a $150M share offering to fund further development.

$SLSMedAI 8/10

SELLAS shares jump 157% after company says its leukemia

SELLAS Life Sciences (SLS) shares surged 157% after reporting positive Phase 3 trial results for its leukemia vaccine, galinpepimut-S, showing a 41% reduction in death risk. The stock closed at $19.17, valuing the company at $3.9B. However, after launching a $150M stock offering, shares dropped 10-13% in after-hours trading. The trial enrolled 126 patients, with median survival of 24.0 months vs. 14.7 months for existing treatments. The company plans to file for regulatory approval in 2027.